Literature DB >> 12466248

Presynaptic cross-talk of beta-adrenoreceptor and 5-hydroxytryptamine receptor signalling in the modulation of glutamate release from cerebrocortical nerve terminals.

Su-Jane Wang1, Victoria Coutinho, Talvinder S Sihra.   

Abstract

1. The presynaptic interactions between facilitatory beta-adrenoreceptors and inhibitory 5-hydroxytryptamine (5-HT) receptors modulating glutamate release from cerebrocortical nerve terminals were examined. 2. 4-aminopyridine (4-AP, 1 mM)-evoked glutamate release was facilitated by the membrane permeant cyclic-3',5'-adenosine monophosphate (cAMP) analogue, 8-bromo-cAMP (8-Br-cAMP), used to directly activate cAMP-dependent protein kinase (PKA). 3. The beta-adrenoreceptor agonist, isoprenaline (ISO), effected a concentration-dependent potentiation of 4-AP-evoked glutamate release which was abolished by the beta-adrenoreceptor antagonist, propranolol, and the PKA inhibitor, Rp-cyclic-3',5'-adenosine-monophosphothioate (Rp-cAMPS). 4. 5-HT receptor activation by 100 microM 5-HT produced an inhibition of 4-AP-evoked glutamate release in nerve terminals. The inhibitory effect of 5-HT could be mimicked by the selective 5-HT(1A) receptor agonist, 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) and antagonized by 1-(2-methoxyphenyl)-4-(4-phthalimidobutyl)piperazine (NAN-190). 5. When 5-HT (or 8-OH-DPAT) was used in conjunction with ISO or 8-Br-cAMP, the beta-adrenoreceptor- and PKA-mediated potentiation of glutamate release was abrogated. 6. The inhibitory crosstalk of 5-HT(1A) receptors to beta-adrenoceptor-mediated facilitation of glutamate release was abolished in the presence of NAN-190. 7. Examination of voltage-dependent Ca(2+) influx revealed that, while ISO and 5-HT alone caused a respective potentiation and diminution of the 4-AP-evoked increase in [Ca(2+)](c), the co-presence of 5-HT abolished the ISO mediated potentiation of Ca(2+) influx. 8. Together, these results suggest that beta-adrenoreceptors and 5-HT(1A) receptors coexist on the cerebrocortical nerve terminals and that the cross-talk between the two receptor signalling pathways occurs at a locus downstream from cAMP production, possibly at the level of voltage-dependent Ca(2+) influx.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466248      PMCID: PMC1573621          DOI: 10.1038/sj.bjp.0705045

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  65 in total

1.  Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats.

Authors:  L V Lopes; R A Cunha; J A Ribeiro
Journal:  J Neurophysiol       Date:  1999-12       Impact factor: 2.714

2.  A modulatory role for protein phosphatase 2B (calcineurin) in the regulation of Ca2+ entry.

Authors:  J R Burley; T S Sihra
Journal:  Eur J Neurosci       Date:  2000-08       Impact factor: 3.386

Review 3.  Adenylate cyclases: critical foci in neuronal signaling.

Authors:  N Mons; D M Cooper
Journal:  Trends Neurosci       Date:  1995-12       Impact factor: 13.837

4.  Endogenous monoamines inhibit glutamate transmission in the spinal trigeminal nucleus of the guinea-pig.

Authors:  R A Travagli; J T Williams
Journal:  J Physiol       Date:  1996-02-15       Impact factor: 5.182

5.  Masking of forskolin-induced long-term potentiation by adenosine accumulation in area CA1 of the rat hippocampus.

Authors:  K T Lu; P W Gean
Journal:  Neuroscience       Date:  1999-01       Impact factor: 3.590

6.  A role for calcineurin (protein phosphatase-2B) in the regulation of glutamate release.

Authors:  T S Sihra; A C Nairn; P Kloppenburg; Z Lin; C Pouzat
Journal:  Biochem Biophys Res Commun       Date:  1995-07-17       Impact factor: 3.575

7.  Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro.

Authors:  G Maura; M Raiteri
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

8.  Isoproterenol potentiates synaptic transmission primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium channels in the rat amygdala.

Authors:  C C Huang; K S Hsu; P W Gean
Journal:  J Neurosci       Date:  1996-02-01       Impact factor: 6.167

9.  Co-existence and interaction between facilitatory and inhibitory metabotropic glutamate receptors and the inhibitory adenosine A1 receptor in cerebrocortical nerve terminals.

Authors:  E Vázquez; D C Budd; I Herrero; D G Nicholls; J Sánchez-Prieto
Journal:  Neuropharmacology       Date:  1995-08       Impact factor: 5.250

10.  GABAB receptor-mediated presynaptic inhibition in guinea-pig hippocampus is caused by reduction of presynaptic Ca2+ influx.

Authors:  L G Wu; P Saggau
Journal:  J Physiol       Date:  1995-06-15       Impact factor: 5.182

View more
  4 in total

1.  Idebenone inhibition of glutamate release from rat cerebral cortex nerve endings by suppression of voltage-dependent calcium influx and protein kinase A.

Authors:  Yi Chang; Yu-Wan Lin; Su-Jane Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-04       Impact factor: 3.000

2.  Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction.

Authors:  Silvia Di Prisco; Elisa Merega; Massimiliano Lanfranco; Simona Casazza; Antonio Uccelli; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 3.  The cellular building blocks of breathing.

Authors:  J M Ramirez; A Doi; A J Garcia; F P Elsen; H Koch; A D Wei
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

4.  Trigeminovascular effects of propranolol in men and women, role for sex steroids.

Authors:  Eloísa Rubio-Beltrán; Rianne M Schoon; Jeffrey van den Berg; Catharina C M Schuiling-Veninga; Birgit C P Koch; Carlos M Villalón; Jorie Versmissen; A H Jan Danser; Anton H van den Meiracker; Khatera Ibrahimi; Antoinette MaassenVanDenBrink
Journal:  Ann Clin Transl Neurol       Date:  2022-08-27       Impact factor: 5.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.